 Michael Rosenberg
Concepts (206)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Atrial Fibrillation | 11 | 2023 | 318 | 3.950 |
Why?
| | Long QT Syndrome | 7 | 2023 | 61 | 3.860 |
Why?
| | Machine Learning | 8 | 2023 | 315 | 2.470 |
Why?
| | Electronic Health Records | 5 | 2022 | 809 | 1.660 |
Why?
| | Anti-Arrhythmia Agents | 3 | 2023 | 105 | 1.560 |
Why?
| | Body Height | 5 | 2017 | 187 | 1.440 |
Why?
| | Defibrillators, Implantable | 7 | 2020 | 282 | 1.110 |
Why?
| | Electrocardiography | 8 | 2023 | 548 | 1.060 |
Why?
| | Torsades de Pointes | 3 | 2021 | 17 | 0.980 |
Why?
| | Death, Sudden, Cardiac | 6 | 2019 | 155 | 0.880 |
Why?
| | Tachycardia, Ventricular | 4 | 2022 | 149 | 0.850 |
Why?
| | Arrhythmias, Cardiac | 4 | 2019 | 273 | 0.830 |
Why?
| | Medical Order Entry Systems | 1 | 2021 | 42 | 0.740 |
Why?
| | Sotalol | 1 | 2019 | 4 | 0.710 |
Why?
| | Phenethylamines | 1 | 2019 | 18 | 0.710 |
Why?
| | Polymorphism, Single Nucleotide | 4 | 2017 | 2038 | 0.670 |
Why?
| | Tachycardia, Supraventricular | 2 | 2021 | 40 | 0.660 |
Why?
| | Pharmaceutical Preparations | 1 | 2021 | 169 | 0.660 |
Why?
| | Adrenergic beta-Antagonists | 2 | 2022 | 298 | 0.640 |
Why?
| | Dihydrotestosterone | 1 | 2018 | 39 | 0.630 |
Why?
| | Decision Support Systems, Clinical | 1 | 2021 | 180 | 0.630 |
Why?
| | Pacemaker, Artificial | 4 | 2023 | 103 | 0.610 |
Why?
| | Risk Assessment | 5 | 2021 | 3021 | 0.600 |
Why?
| | Electrocardiography, Ambulatory | 2 | 2019 | 52 | 0.590 |
Why?
| | Multifactorial Inheritance | 1 | 2017 | 141 | 0.550 |
Why?
| | Sulfonamides | 1 | 2019 | 451 | 0.550 |
Why?
| | Decision Support Techniques | 1 | 2019 | 360 | 0.540 |
Why?
| | Heart Rate | 1 | 2019 | 708 | 0.540 |
Why?
| | Peptide Fragments | 3 | 2014 | 683 | 0.510 |
Why?
| | Aged | 18 | 2023 | 19358 | 0.510 |
Why?
| | Ventricular Dysfunction, Left | 3 | 2015 | 366 | 0.490 |
Why?
| | Accessory Atrioventricular Bundle | 1 | 2014 | 11 | 0.480 |
Why?
| | Endonucleases | 1 | 2014 | 30 | 0.480 |
Why?
| | Procollagen | 1 | 2014 | 21 | 0.480 |
Why?
| | Risk Factors | 15 | 2023 | 8873 | 0.470 |
Why?
| | Heart Failure | 2 | 2023 | 1962 | 0.470 |
Why?
| | Humans | 41 | 2023 | 117051 | 0.450 |
Why?
| | Myocardial Infarction | 1 | 2020 | 960 | 0.450 |
Why?
| | Transforming Growth Factor beta1 | 1 | 2014 | 159 | 0.440 |
Why?
| | Heart Failure, Diastolic | 1 | 2012 | 20 | 0.430 |
Why?
| | Incidence | 6 | 2021 | 2377 | 0.430 |
Why?
| | Genome-Wide Association Study | 3 | 2018 | 1314 | 0.420 |
Why?
| | Coronary Disease | 1 | 2013 | 352 | 0.390 |
Why?
| | Female | 24 | 2022 | 60634 | 0.370 |
Why?
| | Male | 24 | 2022 | 56663 | 0.370 |
Why?
| | Cardiomyopathies | 1 | 2014 | 298 | 0.370 |
Why?
| | Atherosclerosis | 1 | 2013 | 343 | 0.360 |
Why?
| | Catheter Ablation | 3 | 2022 | 282 | 0.340 |
Why?
| | Transcatheter Aortic Valve Replacement | 2 | 2023 | 148 | 0.340 |
Why?
| | Exercise | 2 | 2018 | 1627 | 0.330 |
Why?
| | Aortic Valve Stenosis | 2 | 2023 | 256 | 0.310 |
Why?
| | Proportional Hazards Models | 5 | 2018 | 1105 | 0.290 |
Why?
| | Genetic Predisposition to Disease | 2 | 2018 | 2227 | 0.280 |
Why?
| | Middle Aged | 12 | 2023 | 27172 | 0.280 |
Why?
| | Logistic Models | 2 | 2020 | 1877 | 0.240 |
Why?
| | Longitudinal Studies | 3 | 2018 | 2480 | 0.230 |
Why?
| | United States | 6 | 2019 | 12380 | 0.220 |
Why?
| | Pilot Projects | 3 | 2018 | 1394 | 0.220 |
Why?
| | Heart Conduction System | 1 | 2023 | 81 | 0.220 |
Why?
| | Electric Countershock | 1 | 2023 | 101 | 0.210 |
Why?
| | Natriuretic Peptide, Brain | 2 | 2014 | 105 | 0.210 |
Why?
| | Prospective Studies | 5 | 2019 | 6389 | 0.210 |
Why?
| | Ventricular Premature Complexes | 1 | 2022 | 22 | 0.210 |
Why?
| | Metoprolol | 1 | 2022 | 37 | 0.200 |
Why?
| | Sex Factors | 3 | 2018 | 1758 | 0.200 |
Why?
| | Diastole | 2 | 2012 | 142 | 0.200 |
Why?
| | Artificial Intelligence | 1 | 2023 | 145 | 0.200 |
Why?
| | Tachycardia, Atrioventricular Nodal Reentry | 1 | 2021 | 26 | 0.200 |
Why?
| | Atrial Flutter | 1 | 2021 | 24 | 0.200 |
Why?
| | Cluster Analysis | 1 | 2022 | 478 | 0.190 |
Why?
| | Retrospective Studies | 10 | 2023 | 12825 | 0.190 |
Why?
| | Biomarkers | 3 | 2018 | 3549 | 0.190 |
Why?
| | Drug Dosage Calculations | 1 | 2019 | 21 | 0.180 |
Why?
| | Contraindications, Procedure | 1 | 2019 | 9 | 0.170 |
Why?
| | Hypertension | 2 | 2022 | 1179 | 0.170 |
Why?
| | Myostatin | 2 | 2009 | 26 | 0.170 |
Why?
| | Bradycardia | 1 | 2019 | 48 | 0.170 |
Why?
| | Cell Phone | 1 | 2020 | 79 | 0.170 |
Why?
| | Tachycardia | 2 | 2021 | 47 | 0.170 |
Why?
| | Atrioventricular Block | 1 | 2019 | 31 | 0.170 |
Why?
| | Decision Trees | 1 | 2018 | 82 | 0.160 |
Why?
| | Time Factors | 3 | 2019 | 6240 | 0.160 |
Why?
| | Drug Monitoring | 1 | 2019 | 185 | 0.160 |
Why?
| | Sex Hormone-Binding Globulin | 1 | 2018 | 49 | 0.160 |
Why?
| | Predictive Value of Tests | 2 | 2020 | 1825 | 0.150 |
Why?
| | Nonlinear Dynamics | 1 | 2018 | 90 | 0.150 |
Why?
| | Frailty | 1 | 2019 | 119 | 0.140 |
Why?
| | Adult | 6 | 2023 | 31003 | 0.140 |
Why?
| | Patient Safety | 1 | 2019 | 278 | 0.140 |
Why?
| | Body Weights and Measures | 1 | 2016 | 33 | 0.140 |
Why?
| | Metabolic Diseases | 1 | 2017 | 102 | 0.140 |
Why?
| | Case-Control Studies | 2 | 2020 | 3099 | 0.130 |
Why?
| | Inpatients | 1 | 2019 | 379 | 0.130 |
Why?
| | Down-Regulation | 1 | 2018 | 606 | 0.130 |
Why?
| | Treatment Outcome | 5 | 2023 | 9257 | 0.130 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2019 | 1889 | 0.130 |
Why?
| | Cardiac Resynchronization Therapy | 1 | 2015 | 38 | 0.130 |
Why?
| | Pulmonary Embolism | 1 | 2017 | 180 | 0.130 |
Why?
| | Physicians | 1 | 2023 | 781 | 0.120 |
Why?
| | Sirtuin 2 | 1 | 2014 | 13 | 0.120 |
Why?
| | Multivariate Analysis | 1 | 2018 | 1458 | 0.120 |
Why?
| | Prosthesis Implantation | 1 | 2015 | 139 | 0.110 |
Why?
| | Venous Thromboembolism | 1 | 2017 | 235 | 0.110 |
Why?
| | Algorithms | 1 | 2021 | 1505 | 0.110 |
Why?
| | Primary Prevention | 1 | 2015 | 175 | 0.110 |
Why?
| | Atrial Function, Left | 1 | 2012 | 6 | 0.110 |
Why?
| | Cardiac Pacing, Artificial | 2 | 2023 | 81 | 0.110 |
Why?
| | Prognosis | 2 | 2018 | 3390 | 0.110 |
Why?
| | Longevity | 1 | 2014 | 151 | 0.110 |
Why?
| | Aged, 80 and over | 3 | 2019 | 6453 | 0.110 |
Why?
| | Echocardiography | 1 | 2015 | 564 | 0.110 |
Why?
| | Epidemiologic Methods | 1 | 2012 | 72 | 0.100 |
Why?
| | Follow-Up Studies | 3 | 2019 | 4507 | 0.100 |
Why?
| | Prevalence | 1 | 2018 | 2300 | 0.100 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2014 | 798 | 0.100 |
Why?
| | Fibrosis | 1 | 2014 | 478 | 0.100 |
Why?
| | Echocardiography, Doppler | 1 | 2011 | 93 | 0.100 |
Why?
| | Nuclear Receptor Co-Repressor 1 | 1 | 2011 | 16 | 0.100 |
Why?
| | Receptors, Thyroid Hormone | 1 | 2011 | 20 | 0.100 |
Why?
| | Age Factors | 1 | 2018 | 2951 | 0.090 |
Why?
| | Thyroid Hormones | 1 | 2011 | 55 | 0.090 |
Why?
| | Population Surveillance | 1 | 2013 | 406 | 0.090 |
Why?
| | Thyroid Gland | 1 | 2011 | 84 | 0.090 |
Why?
| | Insulin-Like Growth Factor I | 2 | 2009 | 291 | 0.090 |
Why?
| | Heart Ventricles | 1 | 2015 | 728 | 0.090 |
Why?
| | Blood Flow Velocity | 1 | 2011 | 325 | 0.090 |
Why?
| | Biomechanical Phenomena | 1 | 2012 | 688 | 0.090 |
Why?
| | Heart | 2 | 2010 | 623 | 0.090 |
Why?
| | Cardiomegaly | 1 | 2010 | 166 | 0.090 |
Why?
| | Hypothalamo-Hypophyseal System | 1 | 2011 | 194 | 0.080 |
Why?
| | Kaplan-Meier Estimate | 1 | 2011 | 825 | 0.080 |
Why?
| | Ventricular Fibrillation | 1 | 2009 | 51 | 0.080 |
Why?
| | Anti-Infective Agents, Local | 1 | 2009 | 41 | 0.080 |
Why?
| | Postoperative Complications | 1 | 2019 | 2198 | 0.080 |
Why?
| | Cardiomyopathy, Hypertrophic | 1 | 2009 | 118 | 0.080 |
Why?
| | Muscle Fibers, Skeletal | 1 | 2009 | 192 | 0.080 |
Why?
| | Aortic Valve | 2 | 2023 | 355 | 0.080 |
Why?
| | Gene Deletion | 1 | 2009 | 356 | 0.080 |
Why?
| | TOR Serine-Threonine Kinases | 1 | 2010 | 366 | 0.080 |
Why?
| | Proto-Oncogene Proteins c-akt | 1 | 2009 | 406 | 0.070 |
Why?
| | Myocytes, Cardiac | 1 | 2010 | 472 | 0.070 |
Why?
| | Ethanol | 1 | 2009 | 566 | 0.060 |
Why?
| | Young Adult | 1 | 2020 | 10675 | 0.060 |
Why?
| | Mice | 5 | 2014 | 15309 | 0.060 |
Why?
| | Bundle of His | 1 | 2023 | 15 | 0.060 |
Why?
| | Bundle-Branch Block | 1 | 2023 | 26 | 0.060 |
Why?
| | Nebivolol | 1 | 2022 | 9 | 0.050 |
Why?
| | Atrioventricular Node | 1 | 2021 | 13 | 0.050 |
Why?
| | Focus Groups | 1 | 2023 | 387 | 0.050 |
Why?
| | Mice, Knockout | 3 | 2014 | 2648 | 0.050 |
Why?
| | Stroke Volume | 1 | 2023 | 514 | 0.050 |
Why?
| | Remote Sensing Technology | 1 | 2020 | 11 | 0.050 |
Why?
| | Ambulatory Care | 1 | 2023 | 478 | 0.040 |
Why?
| | Electronics | 1 | 2020 | 70 | 0.040 |
Why?
| | Aging | 1 | 2009 | 1653 | 0.040 |
Why?
| | Body Mass Index | 2 | 2017 | 2070 | 0.040 |
Why?
| | Survival Analysis | 2 | 2014 | 1240 | 0.040 |
Why?
| | Blotting, Western | 2 | 2011 | 1172 | 0.040 |
Why?
| | Mendelian Randomization Analysis | 1 | 2017 | 48 | 0.040 |
Why?
| | Quantitative Trait Loci | 1 | 2018 | 325 | 0.030 |
Why?
| | Diagnosis, Computer-Assisted | 1 | 2015 | 64 | 0.030 |
Why?
| | Survival Rate | 1 | 2019 | 1679 | 0.030 |
Why?
| | Regression Analysis | 1 | 2017 | 971 | 0.030 |
Why?
| | Odds Ratio | 1 | 2017 | 981 | 0.030 |
Why?
| | Enzyme Induction | 1 | 2014 | 90 | 0.030 |
Why?
| | Blood Glucose | 2 | 2016 | 1931 | 0.030 |
Why?
| | NAD | 1 | 2014 | 66 | 0.030 |
Why?
| | Cohort Studies | 2 | 2017 | 5051 | 0.030 |
Why?
| | Ventricular Remodeling | 1 | 2015 | 234 | 0.030 |
Why?
| | Cross-Sectional Studies | 1 | 2023 | 4510 | 0.030 |
Why?
| | Transcriptome | 1 | 2018 | 756 | 0.030 |
Why?
| | Animals | 5 | 2014 | 32737 | 0.030 |
Why?
| | HeLa Cells | 1 | 2014 | 577 | 0.030 |
Why?
| | Lipids | 1 | 2016 | 584 | 0.030 |
Why?
| | Genotype | 1 | 2017 | 1854 | 0.030 |
Why?
| | Reproducibility of Results | 1 | 2019 | 2819 | 0.020 |
Why?
| | Triiodothyronine | 1 | 2011 | 43 | 0.020 |
Why?
| | Thyroxine | 1 | 2011 | 59 | 0.020 |
Why?
| | Thyrotropin | 1 | 2011 | 103 | 0.020 |
Why?
| | Mutant Proteins | 1 | 2011 | 98 | 0.020 |
Why?
| | Hypothyroidism | 1 | 2011 | 67 | 0.020 |
Why?
| | Health Behavior | 1 | 2016 | 709 | 0.020 |
Why?
| | In Situ Hybridization | 1 | 2011 | 301 | 0.020 |
Why?
| | Cell Cycle Proteins | 1 | 2014 | 563 | 0.020 |
Why?
| | Colorado | 1 | 2019 | 4121 | 0.020 |
Why?
| | Blood Pressure | 1 | 2016 | 1618 | 0.020 |
Why?
| | Hypertrophy | 1 | 2009 | 122 | 0.020 |
Why?
| | Infant, Newborn | 1 | 2020 | 5170 | 0.020 |
Why?
| | Bone Development | 1 | 2009 | 53 | 0.020 |
Why?
| | Absorptiometry, Photon | 1 | 2009 | 226 | 0.020 |
Why?
| | Interleukin-1beta | 1 | 2010 | 368 | 0.020 |
Why?
| | Polymerase Chain Reaction | 1 | 2011 | 1001 | 0.020 |
Why?
| | Tibia | 1 | 2009 | 178 | 0.020 |
Why?
| | Adiponectin | 1 | 2009 | 220 | 0.020 |
Why?
| | Practice Guidelines as Topic | 1 | 2015 | 1403 | 0.020 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2009 | 965 | 0.020 |
Why?
| | Interleukin-6 | 1 | 2010 | 673 | 0.020 |
Why?
| | Bone and Bones | 1 | 2009 | 286 | 0.020 |
Why?
| | Bone Density | 1 | 2009 | 444 | 0.020 |
Why?
| | Gene Expression | 1 | 2011 | 1466 | 0.020 |
Why?
| | Mice, Transgenic | 1 | 2010 | 1993 | 0.020 |
Why?
| | Cell Line | 1 | 2009 | 2670 | 0.010 |
Why?
| | Rats | 1 | 2010 | 5172 | 0.010 |
Why?
| | Mice, Inbred C57BL | 1 | 2010 | 4839 | 0.010 |
Why?
| | Inflammation | 1 | 2010 | 2515 | 0.010 |
Why?
| | Insulin | 1 | 2009 | 2135 | 0.010 |
Why?
|
|
Rosenberg's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|